Baseline and disease characteristics
| . | No. (%) . |
|---|---|
| Median age, y (range) | 57 (18-81) |
| Median time from diagnosis of CML, mo | 34 |
| Response to prior interferon alpha therapy | |
| Hematologic failure | 133 (29) |
| Cytogenetic failure | 160 (35) |
| Intolerance | 161 (35) |
| Chromosomal abnormalities | |
| Yes | 74 (16) |
| No | 363 (80) |
| Missing | 17 (4) |
| Splenomegaly more than 0 cm below costal margin | 82 (18) |
| Hemoglobin level less than 100 g/L | 30 (7) |
| WBC count of 50 × 109/L or more | 84 (19) |
| Platelet count more than 450 × 109/L | 147 (32) |
| . | No. (%) . |
|---|---|
| Median age, y (range) | 57 (18-81) |
| Median time from diagnosis of CML, mo | 34 |
| Response to prior interferon alpha therapy | |
| Hematologic failure | 133 (29) |
| Cytogenetic failure | 160 (35) |
| Intolerance | 161 (35) |
| Chromosomal abnormalities | |
| Yes | 74 (16) |
| No | 363 (80) |
| Missing | 17 (4) |
| Splenomegaly more than 0 cm below costal margin | 82 (18) |
| Hemoglobin level less than 100 g/L | 30 (7) |
| WBC count of 50 × 109/L or more | 84 (19) |
| Platelet count more than 450 × 109/L | 147 (32) |
N = 454. Data are number (%) unless otherwise indicated.
WBC indicates white blood cell.